• Stake sale overhang: ChrysCapital and Sepia Investments offloaded a 7.3% stake from their 21% holding, leaving a remaining 14% block, though management noted no indication of further imminent sell-offs.
• Financial growth targets: The company guided for 15% organic revenue growth and 20% annual PAT growth over the next three to five years, aiming for a 24% EBITDA margin within four to five years as operating leverage improves by the end of FY27.
• Engine brand performance: The portfolio is anchored by 32 engine brands—led by champion brands B29 and MyoRil—which contribute 76% of total revenue and are growing at 19%, roughly double the broader market rate.
• Acquired brand outlook: Corona Remedies expects the Bayer portfolio to reach 25 crore this year and 100 crore within three to four years, alongside plans to double Vodokain revenue over the next three years.